GFIOF
GOLD FIELDS LTD
$39.00
0.00%
No data for this timeframe.
Vol
SEC Reports5
Recent Activity
Jun 3, 2026
SEC
Non-executive director JE McGill acquired 500 ADRs at $37.70 each for a total of $18,850 in an open-market purchase. Thi
6-K — Impact 2/10
May 26, 2026
SEC
Gold Fields reported the results of its 21 May 2026 Annual General Meeting (AGM), confirming that all ordinary and speci
6-K — Impact 2/10
Apr 2, 2026
SEC
Gold Fields Limited filed a 6-K to announce the availability of its 2025 Broad-Based Black Economic Empowerment (B-BBEE)
6-K — Impact 2/10
Analyst Ratings
4Strong Buy
5Buy
4Hold
1Sell
0Strong Sell
Latest Reports
NEUTRAL
6-K
2/10
Non-executive director JE McGill acquired 500 ADRs at $37.70 each for a total of $18,850 in an open-market purchase. Thi
Jun 3, 2026
NEUTRAL
6-K
2/10
Gold Fields reported the results of its 21 May 2026 Annual General Meeting (AGM), confirming that all ordinary and speci
May 26, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
5 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 4 neutral. Avg impact: 3.4/10.
NEUTRAL
6-K
2/10
Non-executive director JE McGill acquired 500 ADRs at $37.70 each for a total of $18,850 in an open-
Jun 3, 2026
NEUTRAL
6-K
2/10
Gold Fields reported the results of its 21 May 2026 Annual General Meeting (AGM), confirming that al
May 26, 2026
NEUTRAL
6-K
2/10
Gold Fields Limited filed a 6-K to announce the availability of its 2025 Broad-Based Black Economic
Apr 2, 2026
NEUTRAL
6-K
4/10
Gold Fields Limited filed a 6-K to announce the publication of its 2025 suite of annual reports, inc
Mar 30, 2026
MIXED
20-F
7/10
Gold Fields reported a strong 2025 with record financials driven by a surge in gold prices and solid
Mar 30, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 64% buy across 14 analysts — 4 strong buy, 5 buy, 4 hold, 1 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $211.5B | 50.8% | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $212.7B | 0.5% | — |
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 5 | 4 | 1 | 0 | 64% | |
| May 1, 2026 | 4 | 5 | 4 | 1 | 0 | 64% | |
| Apr 1, 2026 | 4 | 4 | 4 | 2 | 0 | 57% | |
| Mar 1, 2026 | 4 | 3 | 5 | 2 | 0 | 50% | |
| Feb 1, 2026 | 3 | 3 | 7 | 1 | 0 | 43% | |
| Jan 1, 2026 | 3 | 3 | 8 | 0 | 0 | 43% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.